Literature DB >> 2461296

Antisense RNA inhibits splicing of pre-mRNA in vitro.

S H Munroe1.   

Abstract

Antisense RNAs complementary to human beta-globin pre-mRNA or to a chimeric globin/adenovirus E2a pre-mRNA specifically and efficiently inhibit pre-mRNA splicing in vitro. The level of inhibition depends on the length, position and concentration of the antisense RNA relative to the pre-mRNA substrate. Antisense RNAs complementary to sequences greater than 80 nucleotides downstream of the globin 3' splice site inhibit at least as efficiently as those extending across the splice sites. Thus splicing is sensitive to perturbations involving exon sequences some distance from the splice sites. Inhibition is mediated by factors which affect the annealing of antisense and substrate RNAs. Direct analysis of RNA duplex formation demonstrates the presence of an activity in HeLa cell nuclear extract which promotes the rapid annealing of complementary RNAs in an ATP-independent manner. Both annealing and inhibition are greatly reduced when antisense RNA is added to the splicing reaction greater than or equal to 5 min after substrate. This result may reflect a transition between an open structure, in which annealing of antisense RNA with pre-mRNA is facilitated, and a closed complex in which pre-mRNA is sequestered at an early stage of spliceosome assembly.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461296      PMCID: PMC457123          DOI: 10.1002/j.1460-2075.1988.tb03100.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  43 in total

1.  Exon mutations that affect the choice of splice sites used in processing the SV40 late transcripts.

Authors:  M B Somasekhar; J E Mertz
Journal:  Nucleic Acids Res       Date:  1985-08-12       Impact factor: 16.971

2.  Stepwise assembly of a pre-mRNA splicing complex requires U-snRNPs and specific intron sequences.

Authors:  D Frendewey; W Keller
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

3.  A multicomponent complex is involved in the splicing of messenger RNA precursors.

Authors:  P J Grabowski; S R Seiler; P A Sharp
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

4.  Injected anti-sense RNAs specifically block messenger RNA translation in vivo.

Authors:  D A Melton
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

5.  Trans splicing of mRNA precursors in vitro.

Authors:  M M Konarska; R A Padgett; P A Sharp
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

6.  Secondary structure of splice sites in adenovirus mRNA precursors.

Authors:  S H Munroe
Journal:  Nucleic Acids Res       Date:  1984-11-26       Impact factor: 16.971

7.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

8.  A minimal intron length but no specific internal sequence is required for splicing the large rabbit beta-globin intron.

Authors:  B Wieringa; E Hofer; C Weissmann
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

9.  In vitro-synthesized adenovirus 2 messenger RNA precursors are accurately spliced by nuclear extracts.

Authors:  C J Goldenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

10.  Role of intron-contained sequences in formation of moloney murine leukemia virus env mRNA.

Authors:  L S Hwang; J Park; E Gilboa
Journal:  Mol Cell Biol       Date:  1984-11       Impact factor: 4.272

View more
  29 in total

1.  Inhibition of gene expression by a short sense fragment.

Authors:  F H Cameron; P A Jennings
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

2.  Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I.

Authors:  J Trojan; B K Blossey; T R Johnson; S D Rudin; M Tykocinski; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

3.  RNA processing and ribonucleoprotein assembly studied in vivo by RNA transfection.

Authors:  A M Kleinschmidt; T Pederson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

4.  Exon definition may facilitate splice site selection in RNAs with multiple exons.

Authors:  B L Robberson; G J Cote; S M Berget
Journal:  Mol Cell Biol       Date:  1990-01       Impact factor: 4.272

5.  EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.

Authors:  K Tanaka; T Iwakuma; K Harimaya; H Sato; Y Iwamoto
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

6.  The translational requirement for complete La Crosse virus mRNA synthesis is cell-type dependent.

Authors:  R Raju; L Raju; D Kolakofsky
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

Review 7.  Long noncoding RNAs: past, present, and future.

Authors:  Johnny T Y Kung; David Colognori; Jeannie T Lee
Journal:  Genetics       Date:  2013-03       Impact factor: 4.562

8.  Antisense RNA inhibition of beta-glucuronidase gene expression in transgenic tobacco plants.

Authors:  L S Robert; P A Donaldson; C Ladaique; I Altosaar; P G Arnison; S F Fabijanski
Journal:  Plant Mol Biol       Date:  1989-10       Impact factor: 4.076

9.  Cell type-specific transcriptional regulation of the human adenosine deaminase gene.

Authors:  D L Lattier; J C States; J J Hutton; D A Wiginton
Journal:  Nucleic Acids Res       Date:  1989-02-11       Impact factor: 16.971

10.  Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen.

Authors:  M Schinke; O Baltatu; M Böhm; J Peters; W Rascher; G Bricca; A Lippoldt; D Ganten; M Bader
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.